Limus-based devices, rather than being a substitute for paclitaxel as they were once seen, are coming of age in peripheral ...

The initial long-term results from EFEMORAL I were presented today by Principal Investigator Prof. Andrew Holden (Auckland ...

Purpose: The mechanism of action and pharmacokinetics of sirolimus when used as part of a drug-eluting stent (DES) and the efficacy and cost of using DESs versus bare-metal stents are discussed.

Tampa (Florida) [US], January 21: Concept Medical Inc. (CMI), a global leader in innovative drug-delivery technology across vascular interventions, proudly announces the successful completion of ...

Sirolimus 1mg/mL; contains alcohol. Sirolimus inhibits T-lymphocyte activation and proliferation that occurs in response to antigenic and cytokine (IL-2, IL-4, and IL-15) stimulation by a ...

Coverage by TCTMD has highlighted these findings, underscoring sirolimus-based therapy as a viable new option in below-the-knee interventions. Delhi Assembly Elections 2025: Former CM Arvind ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

Although sirolimus-eluting stents reduce the need for target-vessel revascularization, the lack of randomized trials and greater procedural costs currently restricts their use. Valgimigli and ...

The investigators analyzed data from the cohort of 1,012 patients recruited to the Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization (SIRTAX) trial. 3 Participants ...